Advanced search
Publication Cover
Clinical Ophthalmology Volume 2, 2008 - Issue 4
Submit an article Journal homepage
65
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration

P William ConradDepartment of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA
,
David N ZacksDepartment of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA
&
Mark W JohnsonDepartment of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USACorrespondence[email protected]
Pages 727-733 | Published online: 05 Dec 2008

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

F Semeraro, F Morescalchi, S Duse, F Parmeggiani, E Gambicorti & C Costagliola. (2013) Aflibercept in wet AMD: specific role and optimal use. Drug Design, Development and Therapy 7, pages 711-722.
Read now
Angela M Carneiro, Luis S Mendonça, Manuel S Falcão, Sofia L Fonseca, Elisete M Brandão & Fernando M Falcão-Reis. (2012) Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting. Clinical Ophthalmology 6, pages 1149-1157.
Read now
Uri Soiberman & Anat Loewenstein. (2010) Bevacizumab versus ranibizumab for the treatment of neovascular age-related macular degeneration. Expert Review of Ophthalmology 5:5, pages 603-615.
Read now

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.